SI3548026T1 - 5-((4-(2-(5-(1-hidroksietil)piridin-2-il)etoksi)fenil)metil)-1,3- tiazolidin-2,4-dion za zdravljenje nealkoholne maščobne jetrne bolezni - Google Patents
5-((4-(2-(5-(1-hidroksietil)piridin-2-il)etoksi)fenil)metil)-1,3- tiazolidin-2,4-dion za zdravljenje nealkoholne maščobne jetrne bolezniInfo
- Publication number
- SI3548026T1 SI3548026T1 SI201730714T SI201730714T SI3548026T1 SI 3548026 T1 SI3548026 T1 SI 3548026T1 SI 201730714 T SI201730714 T SI 201730714T SI 201730714 T SI201730714 T SI 201730714T SI 3548026 T1 SI3548026 T1 SI 3548026T1
- Authority
- SI
- Slovenia
- Prior art keywords
- thiazolidine
- dione
- pyridin
- ethoxy
- hydroxyethyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16382584 | 2016-12-01 | ||
| EP17817175.7A EP3548026B1 (en) | 2016-12-01 | 2017-12-01 | 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione for treating nonalcoholic fatty liver disease |
| PCT/IB2017/057587 WO2018100557A1 (en) | 2016-12-01 | 2017-12-01 | 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine- 2,4-dione for treating nonalcoholic fatty liver disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3548026T1 true SI3548026T1 (sl) | 2021-07-30 |
Family
ID=57517838
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201730714T SI3548026T1 (sl) | 2016-12-01 | 2017-12-01 | 5-((4-(2-(5-(1-hidroksietil)piridin-2-il)etoksi)fenil)metil)-1,3- tiazolidin-2,4-dion za zdravljenje nealkoholne maščobne jetrne bolezni |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US11938122B2 (sl) |
| EP (1) | EP3548026B1 (sl) |
| JP (1) | JP7040798B2 (sl) |
| KR (1) | KR102595034B1 (sl) |
| CN (1) | CN110022877B (sl) |
| AU (1) | AU2017370003B2 (sl) |
| BR (1) | BR112019011334A2 (sl) |
| CA (1) | CA3044364A1 (sl) |
| CY (1) | CY1124116T1 (sl) |
| DK (1) | DK3548026T3 (sl) |
| EA (1) | EA201991304A1 (sl) |
| ES (1) | ES2867300T3 (sl) |
| HR (1) | HRP20210576T1 (sl) |
| HU (1) | HUE054346T2 (sl) |
| LT (1) | LT3548026T (sl) |
| MX (1) | MX2019006066A (sl) |
| PL (1) | PL3548026T3 (sl) |
| PT (1) | PT3548026T (sl) |
| SI (1) | SI3548026T1 (sl) |
| WO (1) | WO2018100557A1 (sl) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11938122B2 (en) | 2016-12-01 | 2024-03-26 | Minoryx Therapeutics S.L. | 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3- thiazolidine-2,4-dione for treating nonalcoholic fatty liver disease |
| EP3801515A1 (en) | 2018-06-06 | 2021-04-14 | Minoryx Therapeutics S.L. | 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione and its salts for use in the treatment of mitochondrial diseases |
| EP4142720A1 (en) | 2020-04-30 | 2023-03-08 | Minoryx Therapeutics S.L. | Leriglitazone for treating lung inflammation and interstitial lung disease |
| WO2024141951A1 (en) | 2022-12-28 | 2024-07-04 | Minoryx Therapeutics S.L. | Optimized dosing of leriglitazone |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5441971A (en) | 1991-04-11 | 1995-08-15 | The Upjohn Company | Thiazolidinedione derivatives, production and use thereof |
| DE69231886T2 (de) | 1991-04-11 | 2002-03-28 | Pharmacia & Upjohn Co., Kalamazoo | Thiazolidindionderivate, herstellung und anwendung |
| WO1993022445A1 (en) | 1992-05-05 | 1993-11-11 | The Upjohn Company | A process for producing pioglitazone metabolite |
| US5952509A (en) | 1996-06-27 | 1999-09-14 | Takeda Chemical Industries, Ltd. | Production of benzaldehyde compounds |
| US6191154B1 (en) | 1998-11-27 | 2001-02-20 | Case Western Reserve University | Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases |
| US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| US6720001B2 (en) | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
| US20050107450A1 (en) | 2001-12-21 | 2005-05-19 | Brown Kathleen K. | Dosing regimen for ppar-gamma activators |
| US8993773B2 (en) | 2002-07-16 | 2015-03-31 | Cadila Healthcare Limited | Process to prepare pioglitazone via several novel intermediates |
| GB0510469D0 (en) * | 2005-05-23 | 2005-06-29 | Leuven K U Res & Dev | Insulin sensitization to slow down pubertal tempo and to augment pubertal growth |
| CN101454005B (zh) | 2006-03-16 | 2013-01-02 | 新陈代谢解决方案开发公司 | 用于治疗代谢性炎症介导的疾病的噻唑烷二酮类似物 |
| US8722710B2 (en) | 2007-09-26 | 2014-05-13 | Deuterx, Llc | Deuterium-enriched pioglitazone |
| US8895536B2 (en) | 2010-10-29 | 2014-11-25 | Infirst Healthcare Ltd. | Compositions and methods for treating chronic inflammation and inflammatory diseases |
| WO2013040419A1 (en) | 2011-09-14 | 2013-03-21 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for treating hyperprolinemia-associated mental disorders |
| US8865747B2 (en) | 2012-03-23 | 2014-10-21 | Fundació Institute D'Investigació Biomėdica de Bellvitge (IDIBELL) | Pioglitazone for use in the treatment of adrenoleukodystrophy |
| US20140178456A1 (en) | 2012-08-30 | 2014-06-26 | Udaya Sankar Devanaboyina | Methods and compositions for treating type 2 diabetes and related conditions |
| CA2941562C (en) | 2013-03-14 | 2021-09-21 | Deuterx, Llc | Deuterium-enriched 2,4-thiazolidinediones and methods of treatment |
| WO2015109037A1 (en) | 2014-01-15 | 2015-07-23 | Deuterx, Llc | Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone |
| CN106470991B (zh) * | 2014-04-02 | 2020-07-31 | 米尼奥尔克斯治疗有限公司 | 在中枢神经系统障碍治疗中的2,4-噻唑烷二酮衍生物 |
| US11938122B2 (en) | 2016-12-01 | 2024-03-26 | Minoryx Therapeutics S.L. | 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3- thiazolidine-2,4-dione for treating nonalcoholic fatty liver disease |
-
2017
- 2017-12-01 US US16/465,043 patent/US11938122B2/en active Active
- 2017-12-01 JP JP2019529165A patent/JP7040798B2/ja active Active
- 2017-12-01 SI SI201730714T patent/SI3548026T1/sl unknown
- 2017-12-01 BR BR112019011334A patent/BR112019011334A2/pt unknown
- 2017-12-01 ES ES17817175T patent/ES2867300T3/es active Active
- 2017-12-01 MX MX2019006066A patent/MX2019006066A/es unknown
- 2017-12-01 PT PT178171757T patent/PT3548026T/pt unknown
- 2017-12-01 KR KR1020197019093A patent/KR102595034B1/ko active IP Right Grant
- 2017-12-01 CA CA3044364A patent/CA3044364A1/en active Pending
- 2017-12-01 HU HUE17817175A patent/HUE054346T2/hu unknown
- 2017-12-01 WO PCT/IB2017/057587 patent/WO2018100557A1/en active Search and Examination
- 2017-12-01 AU AU2017370003A patent/AU2017370003B2/en active Active
- 2017-12-01 EP EP17817175.7A patent/EP3548026B1/en active Active
- 2017-12-01 LT LTEP17817175.7T patent/LT3548026T/lt unknown
- 2017-12-01 PL PL17817175T patent/PL3548026T3/pl unknown
- 2017-12-01 CN CN201780074388.1A patent/CN110022877B/zh active Active
- 2017-12-01 EA EA201991304A patent/EA201991304A1/ru unknown
- 2017-12-01 DK DK17817175.7T patent/DK3548026T3/da active
-
2021
- 2021-04-12 HR HRP20210576TT patent/HRP20210576T1/hr unknown
- 2021-04-16 CY CY20211100335T patent/CY1124116T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017370003A1 (en) | 2019-06-06 |
| AU2017370003B2 (en) | 2023-04-13 |
| JP7040798B2 (ja) | 2022-03-23 |
| EP3548026A1 (en) | 2019-10-09 |
| BR112019011334A2 (pt) | 2019-10-15 |
| PL3548026T3 (pl) | 2021-08-23 |
| DK3548026T3 (da) | 2021-04-19 |
| EA201991304A1 (ru) | 2019-12-30 |
| HRP20210576T1 (hr) | 2021-05-28 |
| KR102595034B1 (ko) | 2023-10-26 |
| CY1124116T1 (el) | 2022-05-27 |
| EP3548026B1 (en) | 2021-01-20 |
| JP2020500868A (ja) | 2020-01-16 |
| HUE054346T2 (hu) | 2021-08-30 |
| CA3044364A1 (en) | 2018-06-07 |
| LT3548026T (lt) | 2021-05-25 |
| PT3548026T (pt) | 2021-04-22 |
| WO2018100557A1 (en) | 2018-06-07 |
| MX2019006066A (es) | 2019-09-10 |
| US20200093812A1 (en) | 2020-03-26 |
| CN110022877B (zh) | 2023-06-23 |
| CN110022877A (zh) | 2019-07-16 |
| KR20190086766A (ko) | 2019-07-23 |
| US11938122B2 (en) | 2024-03-26 |
| ES2867300T3 (es) | 2021-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI3548026T1 (sl) | 5-((4-(2-(5-(1-hidroksietil)piridin-2-il)etoksi)fenil)metil)-1,3- tiazolidin-2,4-dion za zdravljenje nealkoholne maščobne jetrne bolezni | |
| IL267557B (en) | Process for the preparation of 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl[ethoxy]phenyl]methyl]-2,4-thiazolidinedione and their salts | |
| EA202091120A3 (ru) | Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы | |
| DK2598501T3 (da) | N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamidmesylat-monohydrat | |
| EP3376866A4 (en) | 4 - ((6-2- (2,4-DIFLUOROPHENYL) -1,1-DIFLUORO-2-YL) PROPYL) PYRIDIN-3-YL) OXY) BENZONITRILE AND METHODS FOR PREPARING THE SAME | |
| HK1255438A1 (zh) | 用於治療癌症的(s，e)-3-(6-氨基吡啶-3-基)-n-((5-(4-(3-氟-3-甲基吡咯烷-l-羰基)苯基)-7-(4-氟苯基)苯並呋喃-2-基)甲基)丙烯酰胺 | |
| SI2632921T1 (sl) | Polimorfi in soli 6-(1H- indol-4-il)-4-(5-((4-(1-metiletil)-1-piperazinil)metil)-1,3-oksazol-2- il)-1H-indazola kot inhibitorji PI3K za uporabo pri zdravljenju npr. respiratornih motenj | |
| RS60764B1 (sr) | Derivati 5-[2-(piridin-2-ilamino)-1,3-tiazol-5-il]-2,3-dihidro-1h-izoindol-1-ona i njihova upotreba kao dvojnih inhibitora fosfatidilinozitol 3-kinaze delta i gama | |
| IL279183A (en) | Method for administering a therapeutically effective amount of 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1, 3-thiazolidine-2, 4-dione | |
| IL272992A (en) | Solid structures of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide | |
| HK1246290A1 (zh) | 用於製備ｌ-丙氨酰-l-丙氨酸2-{4-[2-({[2(4-氯苯基)-1，3-噻唑-４-基]甲基}硫烷基)-3，5-二氰基-6-(吡咯烷-1-基)吡啶-4-基]苯氧基}乙酯單鹽酸鹽的方法 | |
| IL279186A (en) | Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1, 3-thiazolidine-2, 4-dione and their salts | |
| EP3541797A4 (en) | 4 - ((6- (2- (2,4-DIFLUORPHENYL) -1,1-DIFLUOR-2-HYDROXY-3- (5-MERCAPTO-1H | |
| HK1222655A1 (zh) | -{ }- -{ -嗎啉基甲基 -吡咯- -基 亞甲基}- -氧代- -二氫- -吲哚- -基 甲基 -噻唑烷- -二酮的新型鹽、其製備以及包含其的製劑 |